Fractyl Health faces Nasdaq delisting notice
Fractyl Health faces a Nasdaq delisting proceeding over its sub‑$1.00 share price but plans a hearing request and a potential reverse split to seek compliance.
Rhea-AI Filing Summary
Fractyl Health, Inc. (GUTS) reports that Nasdaq has notified the company its common stock is subject to delisting from the Nasdaq Global Market because it did not regain compliance with the $1.00 minimum bid price requirement within the 180-day grace period that ended September 9, 2026. The company plans to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting while the hearings process is pending, so the stock is expected to continue trading on Nasdaq during that time. Fractyl has already filed a proxy statement seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-15 as a potential way to restore compliance by achieving a closing bid of at least $1.00 per share for the required 10 to 20 consecutive business days.
Positive
- None.
Negative
- Nasdaq delisting risk: GUTS failed to meet the $1.00 minimum bid price for 30 consecutive business days and did not regain compliance within the 180-day grace period ending September 9, 2026, leading Nasdaq to initiate a process to delist the company’s securities.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum bid price requirement: $1.00 per share
Consecutive days below $1.00 triggering deficiency: 30 business days
Grace period length: 180 calendar days
+4 more
7 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5450(a)(1) continued listing standard
Consecutive days below $1.00 triggering deficiency
30 business days
Period during which GUTS traded below the minimum bid price
Grace period length
180 calendar days
Time allowed to regain compliance ending September 9, 2026
Initial deficiency notice date
March 13, 2026
Date Nasdaq first notified Fractyl Health of non-compliance
Delisting notice date
September 10, 2026
Date Nasdaq stated the securities are subject to delisting
Required compliant trading period
10–20 consecutive business days
Days at or above $1.00 closing bid to regain compliance
Proposed reverse split ratio range
1-for-5 to 1-for-15
Range in proxy seeking stockholder approval filed August 24, 2026
Key Terms
Minimum Bid Price Requirement, Nasdaq Global Market, Nasdaq Hearings Panel, reverse split, +1 more
5 terms
Minimum Bid Price Requirement market
"not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Global Market market
"for continued listing on the Nasdaq Global Market, as the minimum bid"
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
Nasdaq Hearings Panel regulatory
"subject to delisting from Nasdaq unless the Company timely requests a hearing"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
reverse split financial
"to effect a reverse split of the Company’s outstanding common stock"
A reverse split is when a company reduces the number of its outstanding shares by combining several existing shares into one new share, so the price per share rises proportionally while the company’s overall value stays the same. Investors care because it can make a stock appear more respectable or meet exchange rules — like turning many small coins into a single larger bill — but it can also signal financial trouble and often affects trading liquidity and investor perception.
emerging growth company regulatory
"Emerging growth company Item 3.01 Notice of Delisting"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Fractyl Health (GUTS) receive a Nasdaq delisting notice?
Fractyl Health received a Nasdaq notice because its common stock’s minimum bid price stayed below $1.00 per share for 30 consecutive business days and the company did not regain compliance within the 180-day grace period that ended on September 9, 2026.
Is Fractyl Health’s GUTS stock being delisted from Nasdaq now?
Not immediately. Nasdaq notified Fractyl Health on September 10, 2026 that its securities are subject to delisting, but the company intends to request a hearing. That hearing request will automatically stay any suspension or delisting while the hearings process is ongoing.
What must Fractyl Health (GUTS) do to regain Nasdaq bid price compliance?
To regain compliance with Nasdaq Listing Rule 5450(a)(1), the company’s common stock must have a closing minimum bid price of at least $1.00 per share for at least 10 consecutive business days and up to 20 consecutive business days at Nasdaq staff’s discretion.
What reverse split is Fractyl Health proposing to help GUTS regain compliance?
On August 24, 2026, Fractyl Health filed a proxy statement seeking stockholder approval to effect a reverse split of its outstanding common stock at a ratio between 1-for-5 and 1-for-15, intended as a potential means to meet the minimum bid price requirement.
When did Nasdaq first notify Fractyl Health (GUTS) about the bid price deficiency?
Nasdaq’s Listing Qualifications Department first notified Fractyl Health on March 13, 2026 that its common stock was not in compliance with the Minimum Bid Price Requirement because the stock traded below $1.00 per share for 30 consecutive business days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
